Publication | Closed Access

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial

Pancreatic CancerAfugem GercorGastrointestinal OncologyMedicineMetastatic Pancreatic AdenocarcinomaPharmacologyRandomised Phase 2PharmacotherapyCancer TreatmentOncologyMolecular Oncology